Scimitar Equity Blog

Categories

• $16.7M to Fund CLT-008 for ARS
• $3M Award to Develop Gene
• 18 month outcomes from its APOLLO trial
• A Daily Look
• A prayer for those dead
• Aastrom Biosciences
• Aastrom Biosciences (ASTM)
• Acquisition
• ACTC.OB
• ACTCellerate™ Cell Lines
• Acute Mycardial Infaraction (AMI) Update and Review
• Acute Radiation Syndrome (ARS)
• Adam Feuerstein
• adult stem cells
• Advanced Cell Technology
• Advanced Cell Technology (ACTC.OB)
• advocacy coalition
• AFIRM
• AHA Update
• Alchemia (ASX: ACL)
• Aldagen
• Aldargen
• Alliance Defense Fund
• Allogeneic cell-based therapy
• ALS Clinical Trial
• Alzheimer's disease
• AMEX: BTX
• AMEX: CUR
• AMEX: NBS
• Amicus Brief
• Amicus Curiae Filing
• An Expanded Market Oppurtunity
• An extra $1B for the NIH?
• An Objective Opinion
• Anaplastic Thyroid Cancer
• AnC Bio Holdings
• Angelman Syndrome
• Angiochem
• APOLLO study
• APOLLO Trial demonstrated Safety & Feasibility and Improvements in Cardiac Function
• ASTM
• ASX: MSB
• At-the-Market (ATM) Offerings
• Athersys (ATHX)
• Athersys (NASDAQ: ATHX)
• Autologous cell therapy
• basal cell carcinomas (BCCs)
• Batten disease
• BAXTER
• Baxter Ventures
• BBRI
• Bio Medicine
• Bioheart (OTCBB: BHRT)
• BioLife Solutions (OTC BLFS)
• Biomedical CEO survey
• Biomet Biologics
• BioMimetic Therapeutics
• BioMimetic Therapeutics (BMTI)
• Biopolymer Microthreads
• BioRestorative Therapies (OTC: BRTXD)
• Biotech Leads by Percentage in Q/2/10
• Biotechnology Tax Breaks
• BioTime (AMEX:BTX)
• BioTime (NYSE MKT: BTX)
• BLA Approval
• Bluebird bio
• Board of Director's appointment
• Boston Biomedical Research Institute
• Brainstorm Therapeutics (BCLI.OB)
• Breaking News
• Bright Cell Therapy Study funded by NHLBI/NIH
• California Institute for Regenerative Medicine (CIRM)
• cancer
• Cancer Costs to rise as US Population Ages
• cancer research
• cancer stem cells
• Capricor
• CAR Gene
• Cardiac Cell Therapy webcast
• Cardio3 BioSciences
• Cardiovascular Licensing Agreement
• Cedars-Sinai Regenerative Medicine Institute
• Cell Stem Cell
• Cell Therapy Companies
• Cellectis SA to acquire Cellartis
• Cellerant Therapeutics
• Cellular Dynamics
• Cellular origins of breast cancer
• Cephalon (CEPH)
• Cevec Pharmaceuticals
• Chemistry Nobel Prize
• Clinical Data from GRNOPC1 Spinal Cord Injury Trial
• Clinical Hold Lifted
• Clinical Trial for DCM
• Clinical Trial for multiple sclerosis-related fatigue (PMSF)
• Co-promotion Sales Agreement
• Collaboration
• Collaboration and License Agreement
• Collaborative Research
• Colon Cancer and detecting Relapse
• Columbia University Medical Center
• commercial sale in India
• Common Stock Exchange for 12/10 Warrants
• Complete sequencing of DNA shows normality of the cells and their suitability for clinical use
• Cord Blood Banks
• Cord Blood Stem Cell Adaptation
• Cord Blood Stem Cells
• Credit Downgrade
• critical limb ischemia
• Crohn's Disease Colitis Model
• Cytomedix (OTC BB:CMXI)
• Cytomedix (OTC QX: CMXI)
• Cytori Therapeutics
• Cytori's PRECISE trial
• Cytovis
• CYTX
• CYTX – Strong BUY
• CYTX earnings call
• CYTX Shareholder Letter
• Daily Look EOD Closing Bell
• Daily Look Starting the Day
• Death of Chairman and CEO
• Defense Advanced Research Projects Agency (DARPA)
• Definitive Merger Agreement
• Dendreon (DNDN)
• Diabetes
• Dickey-Wicker amendment
• Divestiture of Ownership Interest in Suzhou Erye closes
• DOD Award to treat Osteoporosis
• DOD Contract for Brain Cancer Research
• Dosing of HuCNS-SC in PMD Trial completed
• Dr. Robin Smith
• Drug and device reviews
• Dry AMD
• Early-stage Phase I trial
• Earnings Conference Call
• Earnings Report Card
• EB66 duck stem cell technology
• Edward P. Owens
• effective treatment for malignant glioma
• elimination and reductions of debt
• embryonic stem cell research
• Encapsulation and Stem Cell Technologies
• Epigenetics
• equity investment of $7.1M
• EU CE Mark
• European Medicines Agency (EMA)
• Exclusive license agreement
• Expands P2 Trial of ICT-107
• Extension of Warrant Expiration Date
• Fate Therapeutics
• FDA Approves First Cord Blood Product
• FDA Clearance for P3 Bone Marrow Transplant Trial
• FDA Fast Track Designation
• Federal funding of human embryonic stem cell (hESC) research
• Fetal stem cell transplants
• Fibrocell Science
• Finalizes Amorcyte Acquisition
• Financing
• financings
• First ADVANCE trial site to begin enrollment in the Netherlands
• First Clinical Trial using hESCs
• First Patients enrolled in 2 Clinical Trials to treat Stargardt's Disease and Dry Age Macular Degeneration
• Food and Drug Administration (FDA)
• Forecast Issues
• FOXM1 gene
• French Muscular Dystrophy Association (AFM)
• Fresenius Biotech
• Fresenius Biotech’s ATG
• Frozen Blood from Stored Samples
• Fy10 earnings and recap
• FY10 Results
• FY11 & FY12 Achievements and Highlights
• FY11 Results
• FY12 Achievements and Highlights
• Gene Test finds Disease Risk
• Gene Therapy
• Generating Platelets using iPSCs
• Generation of functional dopaminergic neuronal cells
• Genetic Mechanism
• Genetics Policy Institute (GPI)
• GERN
• Geron (GERN)
• GRABM-L (GR N1005 against B rain M etastases – L ung cancer)
• Grant for type 1 diabetes research
• GRN1005 P2 Trial
• GRN163L preclinical data
• Growing back a damaged spine
• Growing blood vessels from human tissues
• Growing heart cells
• Growing New Replacement Joints
• Guidance
• H.R. 6165
• Haemopoietic Stem Cells
• Hamilton Thorne Ltd. (TSX-V: HTL)
• Happy New Year 2011
• Happy New Year 2012
• Happy New Year 2013
• Happy Thanksgiving
• Harris Interactive/HealthDay poll
• Harvard Apparatus Regenerative Technology
• Harvard Bioscience (HBIO)
• Harvard Scientists Report
• Harvest Technologies’
• Healthcare
• Healthcare VC continues to Slide
• Heated gold nanoshells
• HemoGenix®
• Henry McCusker
• Henry W McCusker
• hESC development
• hESC funding Controversy
• hESCs to treat SMD
• Histogenics
• HIV Therapy Findings
• Holiday Achievement
• House Republicans
• HR 6081
• HR 6081 Renewed
• http://www.scimitarequity.com/blog/wp-admin/user-new.php
• Human Cardiomyocyte Product Launches
• Human Stem Cells used to treat Parkinson's
• IBD Phase II Clinical Trial
• IDE clinical trial
• imetelstat (GRN163L)
• Immune Matched Human Parthenogenetic Stem Cells
• ImmunoCellular Therapeutics
• IMUC.OB
• In-house screening of compound libraries
• In-License of Patent Portfolio
• IND Application Cleared
• IND Approval for Major Depression Trial
• IND Filed
• IND for SMD
• Independent Equity Research
• Independent Insight
• induced pluripotent stem (iPS) cells
• Induced pluripotent stem cell lines
• induced pluripotent stem cells technology
• initiates P2 Trial of GRN1005
• Initiates PSTI with a Speculative "BUY" rating
• Initiation Phase II Trial
• intellectual property deals
• IntelliCell (OTCQB: SVFC)
• Interim Results
• Interim results from ASTM’s US Phase 2b RESTORE-CLI trial
• International Stem Cell (ISCO.OB)
• Intestinal Tissue
• iPierian
• iPS Cell Patent in-licensed
• iPS Cell Patents
• iPS-derived heart cells
• IRB Approval
• Is Dilution the only Solution?
• ischemic stroke
• Ischemic Tolerant Stem Cells
• ISCO.OB
• James Sherley
• Join our Community
• Joint Venture
• Juventas Therapeutics
• Karolinska Institutet
• Key Catalysts and Milestones
• Key factors driving growth in stem cells research
• Lack of Funding Stability
• leukemia
• License
• Licenses a clinically active oncology vaccine
• Life Sciences Jobs and Investment Act of 2010
• Life Technologies Corporation (NASDAQ: LIFE)
• Lifeline Skin Care ™.
• Lin28
• livers from stem cells
• LON: RENE
• Long QT syndrome
• Macular Degeneration
• Major Luis Alvarez
• Management Change
• Marketing Agreement
• Maryland Stem Cell Research Commission issues 2012 Requests for Applications (RFAs)
• Maryland Stem Cell Research Fund
• Mass Companies
• Matched maternal blood cells
• Material Transfer Agreement
• Medical College of Wisconsin
• Medistem (MEDS.PK)
• Medtronic (MDT) participated
• MELA Sciences (MELA)
• Memorandum of Understanding
• Merger Agreement
• Merger Negotiations Terminated
• Merger of Glycosan BioSystems
• Merry Christmas
• Mesoblast (ASX: MSB)
• Mesoblast Ltd
• Michael J. Fox Foundation
• Miltenyi Biotec
• miR-34a
• Mirna Therapeutics
• Momentum and Appreciation
• Motor Neurone Disease Research
• MSC's
• MultiStem
• MultiStem therapy for treating stroke
• Muscular Dystrophy
• Myoblast program
• NANEX
• NASDAQ Compliance
• NASDAQ Listing Issue
• NASDAQ: ACTC.OB
• NASDAQ: ASTM
• NASDAQ: ATHX
• Nasdaq: BCLI.OB
• NASDAQ: BMTI
• NASDAQ: CYTX
• NASDAQ: FSC.OB
• NASDAQ: GERN
• NASDAQ: IMUC.OB
• NASDAQ: ISCO.OB
• NASDAQ: KOOL
• NASDAQ: LFE
• NASDAQ: OSIR
• NASDAQ: PSTI
• NASDAQ: STEM
• NASDAQ: STEMD
• NASDAQ: TNGN
• NASDAQ:OPXA
• National Institute of Health(NIH)
• National Securities
• National Securities Corp
• National Securities Downgrade
• National Venture Capital Association (NVCA)
• Nature Biotechnology article
• NBS and Progenitor Cell Therapy (PCT) closed their merger transaction.
• NBS’s Progenitor Cell Therapy (PCT)
• Need for frequent genomic monitoring of pluripotent stem cells
• Neo-Urinary Conduit
• NeoStem
• NeoStem (AMEX: NBS)
• NeoStem (NYSE MKT: NBS)
• Nerve Regeneration
• Neural Stem Cell Therapy
• Neuralstem (AMEX:CUR)
• Neuralstem (AMEX; CUR)
• Neuralstem (NYSE MKT: CUR)
• New ASTM Analyst Review
• New board member
• New Cell Banking Services
• New Cell Lines
• New Cell Lines for Research
• New CEO and Board Member
• New Chairman
• New Chairman & CEO
• New Chairman of CIRM
• New Collaboration
• New COO and acting CEO
• New CYTX Analyst Review
• New Distribution Agreement
• New Embryome Products
• New FDA Reporting Rules
• New Findings
• New Foundational Japanese Patent
• New interim CEO
• New Lead Investor Google Ventures
• New Patent
• New Proxy
• New Scientific Advisory Board Member
• new test for genetic mutations
• New Therapeutic Approach
• New Trial Results
• New Venture Financing
• News
• News from Global Stem Cell Summit
• NHLBI Grant using iPSCs
• NIH Budget
• NIH Funding for Clinical Trials
• Nobel Prize in Medicine
• Noble Capital Markets' Life Sciences Exposition
• Non-exclusive international license
• Non-exclusive license
• Northwest Biotherapeutics (NWBO)
• Notice of Delisting
• NSI-189 IND Application
• NSI189 Safety Depressive Disorder Trial
• NurOwn™ inhibits Sciatic Nerve Injury
• Nuvilex (OTC QB: NVLX)
• NYSE Amex: BTIM
• NYSE Amex: IMUC
• NYSE Amex: NBS
• OncoCyte Corporation
• OncoMed Pharmaceuticals
• Opening the Door to India
• Opexa Therapeutics (OPXA)
• Opinion
• Orphan Drug designation
• Orphan Drug Designation (ODD)
• Orphan Drug Status
• Orthopedic Collaboration
• orthopedic regenerative medicine/biotechnology company
• OSIR Rebounds
• OSIR strengthens mngt team
• OSIR trends higher again
• Osiris Therapeutics
• OTC:BB:ACTC
• Our Stem Cells: The Mystery of Life and Secrets of Healing
• P1 Heart attack trial of its stem cell therapy
• P1 PISCES safety clinical trial
• P2 imetelstat (GRN163L) trial
• P2b RESTORE-CLI Webcast
• P3 study of HA-Irinotecan in metastatic colorectal (bowel) cancer
• Parkinson disease
• Parthenogenesis could treat Inherited Disease
• Parthenogenetic Stem Cell Patent
• Partners with Vatican’s Pontifical Council
• Patent and know-how license agreement with Schepens Eye Research Institute
• Patent Issuance
• Patent Issues
• Patent trouble Ahead?
• Patents
• Patient Enrollment in REVIVE P3 Clinical Trial of Ixmyelocel-T
• Patient Protection and Affordable Care Act of 2010
• Patients with head and neck cancers
• Pay OK for Blood-Based Marrow Cell Donors
• Pelizeaus-Merzbacher Disease (PMD)
• peripheral arterial disease
• Personalized Medicine
• personalized treatment.
• Phase 2 IMPACT-DCM clinical trial extension study
• Phase I clinical trial of MultiStem(R)
• Phase I/II trial
• Phase Ib trial
• Phase II trial clearence
• Phase II/III Clinical Trial in CLI Advances
• Phase IIb TERMS clinical trial
• PI dendritic cell cancer clinical trial
• PI Study of MultiStem
• PII clinical trial for stroke
• Plasticell
• pluripotent stem cell patents
• pluripotent stem cell products
• pluripotent stem cells
• Pluristem (PSTI)
• Pluristem Therapeutics
• Politics
• Positive 12-month final results from the RESTORE-CLI Phase 2 clinical trial
• Positive clinical trials of its adult stem cell product
• Positive Interim Safety Data from Spinal Cord Injury Trial
• Positive P2 Data for Autologous Treatment
• Positive Pre-Clinical Data from Muscle Injury Study
• Positive Results from Phase I Study of MultiStem(R) in Heart Attack Patients
• Positive Results of Bone Marrow Regeneration Trial
• Potential targets for new cancer drugs
• Potential Treatment of Radiation Exposure
• PPACA Grant
• Prader-Willi Syndrome
• pre-CTA consultation meeting
• Preclinical Acute Kidney Injury Study
• Preclinical Results
• Preclinical Study Data of GRNCM1
• Printing Human Skin
• Product Aquisitions
• Progenitor Cell Therapy (PCT) adds to Management
• Promise for Epileptics
• Proposed Public Offering
• Prospectus to register Shares
• Prostate Cancer
• protein-induced pluripotent stem (iPS) cells
• Proteins Found in Muscle Tissue
• Provide stem cell and cancer researchers with leading-edge technologies
• Proxy for Reverse Split
• Prudent Shelf Filing
• Public offering
• Public Offering closes
• Public Offering Completed
• purchase warrants offered
• PureGraft™ System
• Purifying Embryonic Stem Cells
• PwC/NVCA MoneyTree Report
• Q1/11 Results
• Q1/12 Earngs
• Q2 Earnings
• Q2/11 earnings
• Q3/10 Results
• Q3/10 Venture Funding
• Q3/11 Results
• Q3/12
• Q4/10 and FY/10 Results
• Q4/10 results
• Q4/11 and FY 11 Results
• Q4/11 and FY11 Results
• Q4/12 and FY12 Results
• QTDP grants
• Qualifying Therapeutic Discovery Program (QTDP)
• Qualifying Therapeutic Discovery Project
• Quarterlly Achievements
• Quarterly Achievements
• Quarterly Earnings
• Radiation exposure
• Re-nominating Process
• Re-nomination of Bob Klein
• Red Blood Cells from IVF Embryos
• Refocusing cancer research
• Regenerative benefits of MultiStem's therapy
• Regenerative Medicine
• Regenerative Medicine Mid-Week Trend Line
• Regenerative Medicine Promotion Act of 2010
• Regenerative Medicine Weekly Trend Line
• REGENESIS-Phase IIb stroke trial
• Regenicin (OTC BB: RGIN)
• Registered Direct Offering
• RegMed Competitive and Market Intelligence
• RegMed Daily
• RegMed Daily – The Early Movers
• RegMed Daily Closing Bell
• RegMed Daily Dialogue
• RegMed Daily Mid-Day
• RegMed Daily Pre-Open
• RegMed Sector: 10 things you should know of … this morning
• Regulatory Initiatives
• ReNeuron (LON: RENE)
• ReNeuron (LSE:RENE.L)
• Reneuron Group
• ReNeuron Group (RENE.L)
• Repairing cardiac muscles
• Replicating Real Skin
• Replicating the complexity of an organ
• Report Card
• Res-Q™60 BMC System
• Research Note
• Researchers need reliable stem-cell supplies
• Restatement Reclassifies Warrants
• RESTORE-2 study
• RESTORE-CLI trial
• Restoring Partial Spine Mobility
• Retinal Disease Studies
• retinal pigment epithelium (RPE)
• Revascor (TM)
• Reverse stock split
• rheumatoid arthritis
• Roche
• Roche and UCLA Agreement
• Rod Raynovich – Contributor
• Rodman & Renshaw
• Salk Institute for Biological Studies
• Sangamo Biosciences (SGMO)
• SC Proven product Portfolio
• Scale-up initiated
• Science Briefs
• SCRO Approval
• Sector Analysis
• Secured Loan Facility
• Sept4/ARTS pathway
• Series B Venture Financing
• Setback for New Stem Cell Treatment
• Settleing errors involving warrant issuances
• Shelf Filing up to $75M
• Sherley v. Sebelius
• Sherley v. Sebelius case
• Shire
• Short Sellers
• Shutting down cell division could lead to new cancer drugs.
• Sigma-Aldrich
• Signaling Pathways
• Single-blastomere technology Patent
• Sistemic
• Skin Rejuvenation Crèmes
• Sox9
• SPA Agreement
• SPA submitted to FDA
• special protocol assessment (SPA) process
• Spinal Cord Injury Trial
• Stem Cell Banking
• Stem cell breakthrough
• Stem Cell centers for Innovation
• Stem Cell Data to Repair Brain Damage
• Stem cell differentiation protocols
• Stem Cell Disorders
• Stem Cell Gene Linked to Leukemia and Other Cancers
• Stem Cell Line Litigation
• Stem Cell Market
• Stem Cell Research
• Stem Cell Research Advancement Act
• Stem Cell Skin Gun for wound care
• Stem Cell Study helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors
• Stem Cell Technology
• Stem Cell Therapeutic and Research Act
• Stem Cell Therapeutic and Research Reauthorization Act
• Stem Cell Therapeutics (TSX: VENTURE SSS)
• stem cell therapy for severe kidney disease
• Stem Cell Trial in Spinal Cord Injury
• Stem Cell/Regenerative Medicine Universe Earnings
• Stem cells can be targeted in their fight against liver cancer
• Stem Cells Go to War
• Stem for Life Foundation
• Stem Line Litigation
• Stembancc
• StemCellRegenMed
• StemCells
• StemCells (STEM)
• Stemedica
• Stemedica Cell Technology
• Stemgent
• Stemline Therapeutics
• Stemline Therapeutics (STML)
• Stemming
• Stemming by the Glass
• Steve Brozak
• strategic alliance
• strategic equity agreement
• Strategic Equity Agreement Closes
• Strengthened management team
• Suppressing a protein in the blood
• Supreme Court ruling
• Susan G Komen for the Cure
• SynGen
• Synthetic Biology
• Targeting Ischemic Diseases by Improving Blood Flow
• Tay-Sachs disease
• telomerase inhibitor drug
• Temusi CLI phase III Trial Fails
• Tengion
• Tengion (OTC: TNGN)
• TENGION (TNGN-0)
• The Alliance for Regenerative Medicine
• The Daily Dialogue
• The Daily Look
• The Intellectual Property Value
• The issue of liability claims
• The president’s proposed budget
• The RegMed Daily Dialogue
• The Roslin Institute
• The Stem Cell Therapeutic and Research Reauthorization Act of 2010
• The Trend is your Friend
• The Vatican
• The Vatican Response
• The Week: August 2-6/10
• Therapeutic Discovery Project
• Therapeutic Discovery Tax Credit
• Theresa "Tracy" Deisher
• ThermoGenesis (KOOL)
• Thomas B. Okarma Leaves as CEO
• Ticker Symbol Change
• TiGenix (NYSE Euronext: TIG)
• TiGenix (TIG) combination with Cellerix
• TiGenix combination with Cellerix
• TikoMed AB
• TNGN
• Tovaxin® for multiple sclerosis (MS)
• Tracy T. Lefteroff
• Transcription Factors play a role in maintaining Blood Stem Cells
• Transdifferentiation Platform
• Transposagen Biopharmaceuticals
• Treating bowel cancer
• Treating corneal blindness and vision impairment
• Treatment of diabetic foot ulcers and other chronic wounds
• Tribute to an Investment King and Legend
• TSX VENTURE: SSS
• UCSD Awards
• UCSF expanding hESC research
• UK Cancer Stem Cell Consortium
• UK NHS National Innovation Centre
• UMass’ Medical School's Human Stem Cell Bank and Registry
• Uncategorized
• universal red blood cells and platelets
• University of Michigan Comprehensive Cancer Center
• University of Minnesota‘s Masonic Cancer Center
• Unsolicited proposal from TSE:VRX re CEPH
• Update on Neo-Urinary Conduit Clinical Trial
• Updating Skin Care product
• US Army Grant for Traumatic Wounds
• US Court of Appeals for the District of Columbia
• US Patent and Trademark Office
• US Phase 2 IMPACT-DCM clinical trial results
• Valuation
• Vatican and NeoStem (AMEX: NBS) host Adult Stem Cell Meeting
• VEITHsymposium™ non-CME satellite session
• Venture Financing
• Venture series A financing from Bay City Capital LLC
• Verastem
• Verastem (NASDAQ: VSTM)
• ViaCyte (X-Novocell)
• VistaGen (OTCQB: VSTA)
• Vivalis (VLS.PA)
• VSEL™ Technology
• Wake Forest Institute for Regenerative Medicine
• Wall Street Letter
• Warrant Discount Offer
• warrant exercise
• WBB Securities
• William M. Caldwell IV
• Wired Magazine article
• Withdraws plans for IPO
• Worldwide exclusive license
• Wound Care
• Wright Medical Group (WMGI)
• www. Scimitar Equity.com/blog
• www.retailinvestorconferences.com